The FDA has removed R/R PCNSL from a Limitations of Use section on the CAR-T product’s label based on positive findings from ...

Kasey Keller, the USMNT goalkeeper through four FIFA World Cups, discusses his non-Hodgkins lymphoma diagnosis in 2010 and ...

Aleksandra Smith of Millstone prided herself on her blonde hair. But the way she approached losing that typifies how she ...

Nodular sclerosis Hodgkin lymphoma is the most common subtype. It often starts in lymph nodes in the chest or neck and is ...

Dana-Farber Cancer Institute-led research helped drive an FDA label update for axicabtagene ciloleucel (Yescarta) that removes a prior exclusion for patients with primary central nervous system ...

The FDA has approved a label update for axicabtagene ciloleucel (axi-cel; Yescarta), a CD19-directed autologous T-cell ...

Findings could be practice changing if proven prospectively, experts say ...

The U.S. Food and Drug Administration (FDA) has approved an update to the prescribing information for Yescarta (axicabtagene ciloleucel), removing previous limitations of use for adults with relapsed ...

In a first-in-human study, researchers at The University of Texas MD Anderson Cancer Center observed strong responses and early signs of antitumor activity in patients with difficult-to-treat ...

Updated FDA labeling for Yescarta now includes patients with relapsed or refractory primary CNS lymphoma, expanding treatment options for this group.

Some very unfortunate news coming from the Omnium Gatherum camp, as the band took to social media to announce that their ...

Discover how Laverdia CA1 (verdinexor) treats canine lymphoma. Learn about the mechanism of action, handling precautions, and ...